TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Pathophysiology of the Upper Airway in Patients With COPD and Concomitant OSA

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria for COPD Subjects:~* Age range 40-70 years.~* Demonstrated moderate to severe COPD as determined by spirometry (post-bronchodilator spirometry FEV1/FVC \< 0.70 for diagnosing CODP and FEV1\<80% predicted for staging)~* Smoking history of ≥ 10 pack-years~Inclusion Criteria for Control Subjects~* Age range 40-70 years~* Demonstrated no COPD as determined by normal spirometry (post-bronchodilator spirometry FEV1/FVC \> 0.70 for diagnosing CODP and FEV1\<80% predicted for staging)~* No smoking history as defined by less than 100 cigarettes smoked in a lifetime~Exclusion Criteria for both COPD and Control Subjects:~* Metal objects that may interfere with chest CT quantification including presence of a cardiac pacemaker, defibrillator, metal prosthetic heart valve, metal projectile or metal weapon fragment (bullet, shrapnel, shotgun shot) or metal shoulder prosthesis~* Subjects unable to perform spirometry due to:~  * chest or abdominal surgery in the past three months~ * a heart attack in the last three months~ * detached retina or eye surgery in the past three months~ * hospitalization for any other heart problem in the past month~* History of hypersensitivity to Afrin, Lidocaine or albuterol~* A psychiatric disorder, other than mild depression; e.g. schizophrenia, bipolar disorder, major depression, panic or anxiety disorders.~* More than 10 cups of beverages with caffeine (coffee, tea, soda/pop) per day~* Pregnancy or suspected pregnancy

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- COPD Group (Type: ACTIVE_COMPARATOR): Patients who were previously diagnosed of moderate to severe COPD as determined by spirometry. All patients will have sleep and pulmonary physiologic measurements.
- Normal Control Group (Type: ACTIVE_COMPARATOR): Patients who are healthy, without major medical or sleep problems, and have normal spirometry. All patients will have sleep and pulmonary physiologic measurements.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sleep to Your Heart's Content - Insomnia Intervention for Cardiac Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Sleep disturbance as indicated by a score on the Insomnia Severity Index (ISI) of 8 or above.~* Enrolled in the cardiac rehabilitation program offered by the University of Ottawa Heart Institute.~* Willing to be randomized.~* Willing to wear a monitor that tracks sleep and physical activity.~Exclusion Criteria:~* Untreated or undiagnosed obstructive sleep apnea (as per standard cardiac rehabilitation intake assessment, patients with a score of 5 or above on the STOP-BANG (a brief assessment for sleep apnea) will be referred for a sleep assessment by a cardiac rehabilitation physician).~* Unable to converse in English (i.e., while patient materials and questionnaires will be offered in both English and French, the intervention is only offered in English).~* Unable to provide written, informed consent.~* Unable to attend 6 weeks of onsite CBT-I intervention.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CBT-I (Type: EXPERIMENTAL): Participants randomized to receive the intervention will attend 6 weekly group-based CBT-I sessions. Each 90-minute group will include 6-12 participants.
- Wait-list control (Type: NO_INTERVENTION): The wait-list control group will receive treatment as per our standard cardiac rehabilitation program. After completion of the 3-month follow-up questionnaire, wait-list control participants may take part in the intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: DEPOSITION - Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. ≥ 18 years of age~2. Undergoing a cardiac surgical procedure (i.e. isolated coronary artery bypass graft (CABG), isolated single cardiac valve surgery or a combination of both or isolated ascending aorta replacement) with the use of cardiopulmonary bypass (CPB) and median sternotomy~3. Provide written informed consent~Exclusion Criteria:~1. Allergy to tranexamic acid~2. Undergoing minimally invasive surgery~3. Fulfill any of the following transfusion risk factors (A-D):~   A. Emergency surgery B. History of bleeding disorder C. Inherited thromboembolic or hemorrhagic disease D. Infective endocarditis (active)~4. History of previous cardiac surgery~5. Estimated glomerular filtration rate \<30 mL/min (CKD-EPI equation) or on dialysis~6. Pre-operative hemoglobin \> 170 g/L or \<110 g/L~7. Pre-operative thrombocytopenia (\<50,000 platelets per µL)~8. Expected circulatory arrest~9. Pregnancy or breast feeding~10. Previously enrolled in the DEPOSITION trial~11. Refusal of blood products~12. Pericardiectomy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Topical Tranexamic Acid/Placebo (Type: ACTIVE_COMPARATOR): Topical Tranexamic Acid 5g to 10g (50 to 100mL) or placebo. The topical will be poured into the pericardial and mediastinal cavities after protamine administration.
- Intravenous Tranexamic Acid/Placebo (Type: ACTIVE_COMPARATOR): Intravenous Tranexamic Acid 1 to 10g (10 to 100mL) or placebo administered intravenously at the induction of anesthesia as a bolus-infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of RO5186582 in Down Syndrome Among Children 6 to 11 Years of Age

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Down syndrome, except for mosaic Down syndrome~* Available parent or caregiver to attend clinic visits and provide information about the participant's behavior and symptoms~Exclusion Criteria:~* Any primary psychiatric comorbid disorder~* History of infantile spasms, West syndrome, Lennox-Gastaut syndrome, early infantile epileptic encephalopathy, treatment-refractory epilepsy with cognitive/developmental regression, severe head trauma, or central nervous system (CNS) infection~* Seizure event of any type within 12 months prior to Screening or relevant changes in anti-epileptic drugs 6 weeks prior to enrollment~* Significant sleep disruption~* Significant gastrointestinal, renal, hepatic, endocrine, or cardiovascular disease~* New-onset or ongoing hematologic/oncologic disorder~* Severe lactose intolerance~* Participation in another clinical study within 1 month or 6 half-lives prior to first dose, or any extent of participation in Study BP29589 (NCT02451657)

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive matching placebo by mouth (PO) twice daily (BID) for up to 26 weeks.
- RO5186582 120 mg BID (Type: EXPERIMENTAL): Participants will receive RO5186582 at a dosage of 120 milligrams (mg) PO BID for up to 26 weeks.
- RO5186582 40 mg BID (Type: EXPERIMENTAL): Participants will receive RO5186582 at a dosage of 40 mg PO BID for up to 26 weeks.
- RO5186582 60 mg BID (Type: EXPERIMENTAL): Participants will receive RO5186582 at a dosage of 60 mg PO BID for up to 26 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically documented synovial sarcoma.~* Patients with metastatic disease or locally recurrent disease who have failed or refused standard treatment. The disease must be measurable by RECIST.~* Expected survival of at least 6 months.~* Weight at least 35 kg.~* ECOG performance scale 0-2.~* At least 3 weeks since major surgery, and at least 3 weeks since completing radiation therapy or chemotherapy (6 weeks for patients receiving mitomycin C).~* Resolution of toxicity from previous treatment to NCI-CTC grade 1 or less before treatment.~* Adequate bone marrow, renal and hepatic function.~* Able and willing to give valid written informed consent.~Exclusion Criteria:~* Clinically significant heart disease (NYHA Class III or IV).~* Other serious illnesses, e.g. serious infections requiring antibiotics or bleeding disorders.~* History of autoimmune disease.~* Serious intercurrent illness, requiring hospitalization.~* Patients with a second cancer diagnosis in the last five years, except for basal cell carcinoma, completely resected, or cervical carcinoma in situ (CIN), completely resected.~* Known HIV positivity.~* Metastatic disease to the central nervous system for which other therapeutic options, including radiotherapy, may be available.~* Chronic use of immunosuppressive drugs such as systemic corticosteroids.~* Mental impairment that may compromise the ability to give informed consent and comply with the requirements of the study.~* Lack of availability for immunological and clinical follow-up assessments.~* Participation in any other clinical trial involving another investigational agent within 3 weeks prior to enrollment.~* Pregnancy or breast feeding.~* Refusal or inability to use effective means of contraception (all men, and women with childbearing potential).

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ipilimumab (Type: EXPERIMENTAL): Three doses of ipilimumab, 3 mg/kg, were administered by intravenous infusion at 3-week intervals. A 6-week observation period followed the final dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Observational Follow-up Extension Study of AFF002 and AFF004A in Patients With Alzheimer's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* participation in AFF002 and AFF004A~Exclusion Criteria:~* no vaccination with AD02

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Formal Pre-Operative Education

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years or older,~* English as Primary language,~* scheduled to have orthopedic upper extremity surgery.~Exclusion Criteria:~* less than 18 years~* Conservative management or non operative management of orthopedic upper extremity surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Routine Pre-Operative Education in MD office prior to surgery (Type: NO_INTERVENTION): None
- Formal Pre-operative education/therapy prior to surgery (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Robotic Decompression of the Pudendal Nerve in Pudendal Neuralgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 - 70 years old~* Pudendal neuralgia according to Nantes criteria~* pudendal nerve entrapment reachable with robotic transperitoneal approach~Exclusion Criteria:~* bilateral pain~* history of pain ≥ 18 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Non-invasive (Type: NO_INTERVENTION): Neuropathic drugs Pudendal infiltration
- Robotic laparoscopic decompression (Type: EXPERIMENTAL): Robotic laparoscopic decompression of pudendal nerve entrapment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.~Inclusion Criteria:~Subjects who are newly diagnosed with symptomatic MM and who:~* Have not received any prior systemic anti-myeloma therapy~* Have measurable disease~* And are not candidates for high-dose therapy plus stem-cell transplantation (SCT) because of age (≥65 years) or coexisting conditions. Refusal to undergo high dose therapy with SCT is NOT sufficient for entry onto CA204-006 for a subject \<65 years old. There must be a comorbidity that prevents SCT for a subject \<65 years old~Exclusion Criteria:~* Subjects with non-secretory or oligo-secretory or free light-chain only myeloma~* Smoldering MM, defined as asymptomatic MM with absence of lytic bone lesions~* Monoclonal Gammopathy of Undetermined Significance (MGUS)~* Active plasma cell leukemia~* Known Human Immunodeficiency Virus (HIV) infection or active hepatitis A, B, or C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1: Lenalidomide + Dexamethasone (Type: EXPERIMENTAL): Lenalidomide 25 mg capsules by mouth once daily (on Days 1-21), repeat every 28 days until subject meets criteria for discontinuation of study drug~Dexamethasone 40 mg tablets by mouth weekly (on Days 1, 8, 15, 22), repeat every 28 days until subject meets criteria for discontinuation of study drug
- Arm 2: Lenalidomide + Dexamethasone + Elotuzumab (Type: EXPERIMENTAL): Lenalidomide 25 mg capsules by mouth once daily (Days 1-21)~Dexamethasone 28 mg tablets by mouth once daily \[Days 1, 8, 15, 22 (cycles 1 \& 2); Days 1 \& 15(cycles 3-18); Day 1 (cycle 19 \& beyond)\]~Dexamethasone 40 mg tablets by mouth once daily \[Days 8 \& 22 (cycles 3-18); Days 8, 15, 22 (cycle 19 \& beyond)\]~Dexamethasone 8 mg IV (intravenous) solution once daily \[Days 1, 8, 15, 22 (cycles 1 \& 2); Days 1 \& 15 (cycles 3-18); Day 1 (cycle 19 \& beyond)\]~Elotuzumab 10 mg/kg IV solution weekly \[Days 1, 8, 15, 22 (cycles 1 \& 2); Days 1 \& 15 (cycles 3-18)\]~Elotuzumab 20 mg/kg IV solution on Day 1 (cycle 19 \& beyond)~Repeat above-mentioned dose cycles every 28 days until subject meets criteria for discontinuation of study drug

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Anecortave Acetate Risk-Reduction Trial (AART)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Dry AMD in study eye, Wet AMD in non-study eye;~* Other protocol-defined inclusion criteria may apply.~Exclusion Criteria:~* Under 50;~* Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 15 mg Anecortave Acetate (Type: EXPERIMENTAL): Anecortave Acetate Sterile Suspension, 30 mg/mL, one injection of 0.5 mL in the study eye every 6 months for 48 months
- 30 mg Anecortave Acetate (Type: EXPERIMENTAL): Anecortave Acetate Sterile Suspension, 60 mg/mL, one injection of 0.5 mL in the study eye every 6 months for 48 months
- Anecortave Acetate Vehicle (Type: SHAM_COMPARATOR): Anecortave Acetate Vehicle, one sham injection in the study eye every 6 months for 48 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Azithromycin for Children Hospitalized With Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 4-12 years of age~* Admission diagnosis of asthma at the Children's Hospital at Montefiore~* History of persistent asthma (as defined by National Heart, Lung, and Blood Institute)~Exclusion Criteria:~* Concurrent bacterial infection requiring antibiotics~* Antibiotics received within previous 2 weeks~* Contraindication to azithromycin (including allergy to macrolides)~* Chronic lung disease other than asthma (including bronchopulmonary dysplasia, cystic fibrosis, bronchiectasis) or home oxygen requirement~* Immunodeficiency (primary or acquired)~* Chronic systemic steroid use~* Invasive or non-invasive mechanical ventilation required acutely as result of current asthma admission~* Significant cardiac co-morbidity (including hemodynamically significant cardiac disease or arrhythmia)~* Liver disease (hepatitis)~* Pregnancy~* Seizure disorder, currently on anti-epileptic medication)~* Receiving albuterol every 4 hours (q4h) at the time of enrollment~* Previous enrollment in study

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Azithromycin suspension (Type: EXPERIMENTAL): Azithromycin suspension at 10mg/kg/dose (max 500mg)~Once daily for 3 days
- Placebo suspension (Type: PLACEBO_COMPARATOR): Same volume as active drug~Once daily for 3 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment w/ Tri-Luma® Cream & Intense Pulsed Light (IPL) vs a Mild Inactive Control Cream & Intense Pulsed Light (IPL) in Melasma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects diagnosed with moderate to severe melasma on both sides of the face (Investigator's Global Assessment (IGA) at baseline must be 3 or 4.)~Exclusion Criteria:~* Subjects with a diagnosis of skin cancer (Basal Cell Carcinoma (BCC), Squamous Cell Carcinoma (SCC), Melanoma) in the areas to be treated~* Subjects with prior facial Intense Pulsed Light (IPL), resurfacing, deep or chemical peels within 6 months of the date of study entry~* Subject has initiated treatment with hormones including estrogen, progesterone and/or oral contraceptives within 3 months of study entry, or who intend to discontinue hormonal therapy during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- IPL / Tri-Luma® Cream (Type: ACTIVE_COMPARATOR): None
- IPL/Cetaphil® Moisturizing Cream as Inactive Control (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Enoxaparin Sodium on the Incidence of Deep Vein Thrombosis Following Electrophysiology Studies and Radiofrequency Ablation.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing EPS/RFA for the diagnosis and or treatment of SVT based on patient history or ECG evidence.~Exclusion Criteria:~* Patients with a past history of DVT or PE.~* Patients with a history of clotting disorders~* Patients with active malignancies~* Patients requiring full heparinisation during and after the procedure.~* Chronic atrial flutter and atrial fibrillation ablation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- clexane (Type: ACTIVE_COMPARATOR): patients received clexane
- non clexane (Type: NO_INTERVENTION): no clexane given

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues